Role of 11β-hydroxysteroid-dehydrogenase type 1 in the metabolic risk associated with obesity;Rôle de l'enzyme 11β-hydroxystéroïde-déshydrogénase de type 1 dans le risque métabolique associé à l'obésité

Obesite

Volumn 4, Issue 3, 2010, Pages 181-188

  Iovino, A ^a   Paquot, N ^a,b   Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

11 hydroxystero d dehydrogenase type 1; Abdominal obesity; Cortisol; Glucocorticoids; Metabolic syndrome; Selective inhibition; Type 2 diabetes

Indexed keywords

EID: 76149111586     PISSN: 19515995     EISSN: 19516002     Source Type: Journal    
DOI: 10.1007/s11690-009-0204-2     Document Type: Article

References (43)

1. Anagnostis P, Athyros VG, Tziomalos K, et al (2009) The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 94: 2692-701.
2. Björntorp P, Rosmond R (2000) Obesity and cortisol. Nutrition 16: 924-36.
3. Tomlinson JW, Walker EA, Bujalska IJ, et al (2004) 11β-hydroxysteroïd-dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25: 831-66.
4. Vantyghem MC, Marcelli-Tourvieille S, Defrance F, et al (2007) 11β-hydroxystéroïde-déshydrogénase. Avancées récentes. Ann Endocrinol (Paris) 68: 349-56.
5. Iovino A, Scheen AJ (2009) La 11β-hydroxystéroïde-déshydrogénase de type 1: première partie: rôle de l'exposition tissulaire au cortisol dans le risque métabolique lié à l'obésité. Med Mal Metab (sous presse).
6. Iovino A, Scheen AJ (2009) La 11β-hydroxystéroïde-déshydrogénase de type 1: deuxième partie: inhibition sélective pour traiter les anomalies métaboliques associées à l'obésité. Med Mal Metab (sous presse).
7. Bujalska IJ, Kumar S, Stewart PM (1997) Does central obesity reflect "Cushing's disease of the omentum?" Lancet 349: 1210-3.
8. Tomlinson JW, Stewart PM (2004) "Cushing's disease of the omentum": fact or fiction? J Endocrinol Invest 27: 171-4.
9. Walker BR, Andrew R (2006) Tissue production of cortisol by 11β-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann NY Acad Sci 1083: 165-84.
10. Swali A, Walker EA, Lavery GG, et al (2008) 11β-hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia 51: 2003-11.
11. Bujalska IJ, Walker EA, Hewison M, et al (2002) A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid-dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 87: 1205-10.
12. Bujalska IJ, Draper N, Michailidou Z, et al (2005) Hexose-6-phosphate dehydrogenase confers oxoreductase activity upon 11β-hydoxysteroid-dehydrogenase type 1. J Mol Endocrinol 34: 675-84.
13. Stulnig TM, Waldhäusl W (2004) 11β-hydroxysteroid-dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia 47: 1-11.
14. Stimson RH, Andersson J, Andrew R, et al (2009) Cortisol release from adipose tissue by 11β-hydroxysteroid-dehydrogenase type 1 in humans. Diabetes 58: 46-53.
15. Iwasaki Y, Takayasu S, Nishiyama M, et al (2008) Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11β-hydroxysteroid-dehydrogenase type 1) gene. Mol Cell Endocrinol 285: 10-8.
16. London E, Castonguay TW (2009) Diet and the role of 11β-hydroxysteroid-dehydrogenase-1 on obesity. J Nutr Biochem 20: 485-93.
17. Nieuwenhuizen AG, Rutters F (2008) The hypothalamic-pituitary-adrenal axis in the regulation of energy balance. Physiol Behav 94: 169-77.
18. Walker BR (2007) Extra-adrenal regeneration of glucocorticoids by 11β-hydroxysteroid-dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning. Proc Nutr Soc 66: 1-8.
19. Beger J, Tanen M, Elbrecht A, et al (2001) Peroxisome proliferator activated receptor gamma ligands inhibit adipocyte 11β-hydroxysteroid-dehydrogenase type 1 expression and activity. J Biol Chem 276: 12629-35.
20. Wake DJ, Stimson RH, Tan GD, et al (2007) Effects of peroxysome proliferator activated receptor-α and-γ agonists on 11β-hydroxysteroid-dehydrogenase type 1 in sub-cutaneous adipose tissue in men. J Clin Endocrinol Metab 92: 1848-56.
21. Morton NM, Seckl JR (2008) 11β-hydroxysteroid-dehydrogenase type 1 and obesity. Front Horm Res 36: 146-64.
22. Lloyd DJ, Helmering J, Cordover D, et al (2009) Anti-diabetic effects of 11β-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes Metab 11: 688-99.
23. Boyle CD, Kowalski TJ (2009) 11β-hydroxysteroid-dehydrogenase type 1 inhibitors: a review of recent patents. Exp Opin Ther Pat 19: 801-25.
24. Berthiaume M, Laplante M, Festuccia WT, et al (2009) Additive action of 11β-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. Int J Obes 33: 601-4.
25. Basu R, Singh RJ, Basu A, et al (2005) Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J Clin Endocrinol Metab 90: 3919-26.
26. Sandeep TC, Andrew R, Homer NZM, et al (2005) Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54: 872-9.
27. Andrew R, Westerbacka J, Wahren J, et al (2005) The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 54: 1364-70.
28. Basu R, Basu A, Grudzien M, et al (2009) Liver is the site of splanchnic cortisol production in obese non-diabetic humans. Diabetes 58: 39-45.
29. Rask E, Olsson T, Söderberg S, et al (2001) Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86: 1418-21.
30. Stewart PM, Boulton A, Kumar S, et al (1999) Cortisol metabolism in human obesity: Impaired cortisone→cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84: 1022-7.
31. Rask E, Walker BR, Söderberg S, et al (2002) Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid-dehydrogenase type 1 activity. J Clin Endocrinol Metab 87: 3330-6.
32. Stewart PM, Tomlinson JW (2009) Selective inhibitors of 11β-hydroxysteroid-dehydrogenase type 1 for patients with metabolic syndrome, is the target liver, fat, or both? (commentary). Diabetes 58: 14-5.
33. Tomlinson JW, Finney J, Gay C, et al (2008) Impaired glucose tolerance and insulin resistance are associated with increased adipose 11β-hydroxysteroid-dehydrogenase type 1 expression and elevated hepatic 5-alpha-reductase activity. Diabetes 57: 2652-60.
34. Veilleux A, Rhéaume C, Daris M, et al (2009) Omental adipose tissue 11β-HSD1 oxoreductase activity, body fat distribution and metabolic alterations in women. J Clin Endocrinol Metab 94: 3550-7.
35. Purnell JQ, Kahn SE, Samuels MH, et al (2009) Enhanced cortisol production rates, free cortisol, and 11β-HSD1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. Am J Physiol Endocrinol Metab 296: E351-7.
36. Valsamakis G, Anwar A, Tomlinson JW, et al (2004) 11β-hydroxysteroid-dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 89: 4755-61.
37. Tomlinson JW, Stewart PM (2007) Modulation of glucocorticoid action and the treatment of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 21: 607-19.
38. Wamil M, Seckl JR (2007) Inhibition of 11β-hydroxysteroid-dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 12: 504-20.
39. Bujalska IJ, Gathercole LL, Tomlinson JW, et al (2008) A novel selective 11β-hydroxysteroid-dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol 197: 297-307.
40. Courtney R, Stewart PM, Toh M, et al (2008) Modulation of 11β-hydroxysteroid-dehydrogenase (11β-HSD) activity biomarkers and pharmacokinetics of PF-00915275: a selective 11β-HSD1 inhibitor. J Clin Endocrinol Metab 93: 550-6.
41. Hawkins M, Hunter D, Kishore P, et al (2008) INCB013739, a selective inhibitor of 11β-hydroxysteroid-dehydrogenase type 1 (11β-HSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus (Abstract). Diabetes 57 (Suppl. 1): A99-A100.
42. Rosenstock J, Banarer S, Fonseca V, et al (2009) Efficacy and safety of the 11β-HSD1 inhibitor, INCB13739, added to metformin therapy in patients with type 2 diabetes (abstract). Diabetes 59(Suppl. 1): late breaking abstract 7-LB.
43. Ye YL, Zhou Z, Zou HJ, et al (2009) Discovery of novel dual functional agent as PPARgamma agonist and 11β-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem 17: 5722-32.